help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by EWIG, S.
Right arrow Articles by MENSA, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by EWIG, S.
Right arrow Articles by MENSA, J.

Am. J. Respir. Crit. Care Med., Volume 159, Number 6, June 1999, 1835-1842

Pneumonia Acquired in the Community Through Drug-Resistant Streptococcus pneumoniae

SANTIAGO EWIG, MAURICIO RUIZ, ANTONI TORRES, FRANCESC MARCO, JOSE ANTONIO MARTINEZ, MIGUEL SANCHEZ, and JOSEP MENSA

Serveis de Pneumologia i Al·lèrgia Respiratoria, Microbiologia, Malalties Infeccioces, Urgencies, Hospital Clinic, Departament de Medicina, Universitat de Barcelona, Barcelona, Spain

The aim of the study was to determine the incidence of and risk factors for drug resistance of Streptococcus pneumoniae, and its impact on the outcome among hospitalized patients of pneumococcal pneumonia acquired in the community. Consecutive patients with culture-proven pneumococcal pneumonia were prospectively studied with regard to the incidence of pneumococcal drug resistance, potential risk factors, and in-hospital outcome variables. A total of 101 patients were studied. Drug resistance to penicillin, cephalosporin, or a macrolide drug was found in pneumococci from 52 of the 101 (52%) patients; 49% of these isolates were resistant to penicillin (16% intermediate resistance, 33% high resistance), 31% to cephalosporin (22% intermediate and 9% high resistance), and 27% to a macrolide drug. In immunocompetent patients, age > 65 yr was significantly associated with resistance to cephalosporin (odds ratio [OR]: 5.0; 95% confidence interval [CI]: 1.3 to 18.8, p = 0.01), and with the presence of > 2 comorbidities with resistance to penicillin (OR: 4.7; 95% CI: 1.2 to 19.1; p < 0.05). In immunosuppressed patients, bacteremia was inversely associated with resistance to penicillin and cephalosporin (OR: 0.04; 95% CI: 0.003 to 0.45; p < 0.005; and OR: 0.46; 95% CI: 0.23 to 0.93; p < 0.05, respectively). Length of hospital stay, severity of pneumonia, and complications were not significantly affected by drug resistance. Mortality was 15% in patients with any drug resistance, as compared with 6% in those without resistance. However, any drug resistance was not significantly associated with death (relative risk [RR]: 2.5; 95% CI: 0.7 to 8.9; p = 0.14). Moreover, attributable mortality in the presence of discordant antimicrobial treatment was 12%, as compared with 10% (RR: 1.2; 95% CI: 0.3 to 5.3; p = 0.67) in the absence of such treatment. We conclude that the incidence of drug-resistant pneumococci was high. Risk factors for drug resistance included advanced age, comorbidity, and (inversely) bacteremia. Outcome was not significantly affected by drug resistance.




This article has been cited by other articles:


Home page
 ChestHome page
R. Menendez and A. Torres
Treatment Failure in Community-Acquired Pneumonia
Chest, October 1, 2007; 132(4): 1348 - 1355.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. Diaz, P. Barria, M. Niederman, M. I. Restrepo, J. Dreyse, G. Fuentes, B. Couble, and F. Saldias
Etiology of Community-Acquired Pneumonia in Hospitalized Patients in Chile: The Increasing Prevalence of Respiratory Viruses Among Classic Pathogens
Chest, March 1, 2007; 131(3): 779 - 787.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Abgueguen, E. Azoulay-Dupuis, V. Noel, P. Moine, V. Rieux, B. Fantin, and J.-P. Bedos
Amoxicillin Is Effective against Penicillin-Resistant Streptococcus pneumoniae Strains in a Mouse Pneumonia Model Simulating Human Pharmacokinetics
Antimicrob. Agents Chemother., January 1, 2007; 51(1): 208 - 214.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
X. Valles, A. Marcos, M. Pinart, R. Piner, F. Marco, J. M. Mensa, and A. Torres
Hospitalized Community-Acquired Pneumonia Due to Streptococcus pneumoniae: Has Resistance to Antibiotics Decreased?
Chest, September 1, 2006; 130(3): 800 - 806.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. de Roux, M. Cavalcanti, M. A. Marcos, E. Garcia, S. Ewig, J. Mensa, and A. Torres
Impact of Alcohol Abuse in the Etiology and Severity of Community-Acquired Pneumonia
Chest, May 1, 2006; 129(5): 1219 - 1225.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
Y. Fukuda, K. Yanagihara, Y. Higashiyama, Y. Miyazaki, Y. Hirakata, H. Mukae, K. Tomono, Y. Mizuta, K. Tsukamoto, and S. Kohno
Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae
Eur. Respir. J., May 1, 2006; 27(5): 1020 - 1025.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Aspa, O. Rajas, F. Rodriguez de Castro, M. C. Huertas, L. Borderias, F. J. Cabello, J. Tabara, S. Hernandez-Flix, A. Martinez-Sanchis, and A. Torres
Impact of initial antibiotic choice on mortality from pneumococcal pneumonia
Eur. Respir. J., May 1, 2006; 27(5): 1010 - 1019.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
G Barlow and D Nathwani
Is antibiotic resistance a problem? A practical guide for hospital clinicians
Postgrad. Med. J., November 1, 2005; 81(961): 680 - 692.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
N. Kasbekar and P. S. Acharya
Telithromycin: The first ketolide for the treatment of respiratory infections
Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 905 - 916.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
S. I. Pelton and M. R. Hammerschlag
Overcoming Current Obstacles in the Management of Bacterial Community-Acquired Pneumonia in Ambulatory Children
Clinical Pediatrics, January 1, 2005; 44(1): 1 - 17.
[PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. W. R. Pletz, L. McGee, J. Jorgensen, B. Beall, R. R. Facklam, C. G. Whitney, and K. P. Klugman
Levofloxacin-Resistant Invasive Streptococcus pneumoniae in the United States: Evidence for Clonal Spread and the Impact of Conjugate Pneumococcal Vaccine
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3491 - 3497.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
V. Falco, B. Almirante, Q. Jordano, L. Calonge, O. del Valle, C. Pigrau, A. M. Planes, J. Gavalda, and A. Pahissa
Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?
J. Antimicrob. Chemother., August 1, 2004; 54(2): 481 - 488.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. de Roux, M. A. Marcos, E. Garcia, J. Mensa, S. Ewig, H. Lode, and A. Torres
Viral Community-Acquired Pneumonia in Nonimmunocompromised Adults
Chest, April 1, 2004; 125(4): 1343 - 1351.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. E. Singer, I. Harding, M. R. Jacobs, and D. H. Jaffe
Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model
J. Antimicrob. Chemother., May 1, 2003; 51(5): 1269 - 1282.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. G. Campbell, T. J. Marrie, R. Anstey, G. Dickinson, and S. Ackroyd-Stolarz
The Contribution of Blood Cultures to the Clinical Management of Adult Patients Admitted to the Hospital With Community-Acquired Pneumonia: A Prospective Observational Study
Chest, April 1, 2003; 123(4): 1142 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M.A. Marcos, M.T. Jimenez de Anta, J.P. de la Bellacasa, J. Gonzalez, E. Martinez, E. Garcia, J. Mensa, A. de Roux, and A. Torres
Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults
Eur. Respir. J., February 1, 2003; 21(2): 209 - 214.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. Croisier, P. Chavanet, C. Lequeu, A. Ahanou, A. Nierlich, C. Neuwirth, L. Piroth, M. Duong, M. Buisson, and H. Portier
Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones
J. Antimicrob. Chemother., September 1, 2002; 50(3): 349 - 360.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Woodhead
Community-acquired pneumonia in Europe: causative pathogens and resistance patterns
Eur. Respir. J., July 1, 2002; 20(36_suppl): 20S - 27s.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Ortqvist
Treatment of community-acquired lower respiratory tract infections in adults
Eur. Respir. J., July 1, 2002; 20(36_suppl): 40S - 53s.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
W. Bishai
The in vivo-in vitro paradox in pneumococcal respiratory tract infections
J. Antimicrob. Chemother., March 1, 2002; 49(3): 433 - 436.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
I. P. Balcabao, L. Alou, L. Aguilar, M. L. Gomez-Lus, M. J. Gimenez, and J. Prieto
Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones
J. Antimicrob. Chemother., December 1, 2001; 48(6): 907 - 909.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Wilson
Bacteria, antibiotics and COPD
Eur. Respir. J., May 1, 2001; 17(5): 995 - 1007.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. L. Metersky, J. P. Tate, M. J. Fine, M. K. Petrillo, and T. P. Meehan
Temporal Trends in Outcomes of Older Patients With Pneumonia
Arch Intern Med, December 11, 2000; 160(22): 3385 - 3391.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. ARANCIBIA, S. EWIG, J. A. MARTINEZ, M. RUIZ, T. BAUER, M. A. MARCOS, J. MENSA, and A. TORRES
Antimicrobial Treatment Failures in Patients with Community-acquired Pneumonia . Causes and Prognostic Implications
Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 154 - 160.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society